ATE473447T1 - In-vitro-verfahren zum screening zugänglicher biologischer marker in krankhaften geweben - Google Patents

In-vitro-verfahren zum screening zugänglicher biologischer marker in krankhaften geweben

Info

Publication number
ATE473447T1
ATE473447T1 AT06830605T AT06830605T ATE473447T1 AT E473447 T1 ATE473447 T1 AT E473447T1 AT 06830605 T AT06830605 T AT 06830605T AT 06830605 T AT06830605 T AT 06830605T AT E473447 T1 ATE473447 T1 AT E473447T1
Authority
AT
Austria
Prior art keywords
vitro method
biological markers
disease tissues
accessible biological
screening
Prior art date
Application number
AT06830605T
Other languages
English (en)
Inventor
Vincent Castronovo
David Waltregny
Philippe Kischel
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE473447T1 publication Critical patent/ATE473447T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT06830605T 2006-01-07 2006-12-13 In-vitro-verfahren zum screening zugänglicher biologischer marker in krankhaften geweben ATE473447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100141A EP1806587A1 (de) 2006-01-07 2006-01-07 In-vitro-Verfahren zum Screening zugänglicher biologischer Marker in pathologischen Geweben
PCT/EP2006/069679 WO2007080039A1 (en) 2006-01-07 2006-12-13 An in-vitro method for screening accessible biological markers in pathologic tissues

Publications (1)

Publication Number Publication Date
ATE473447T1 true ATE473447T1 (de) 2010-07-15

Family

ID=36021803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830605T ATE473447T1 (de) 2006-01-07 2006-12-13 In-vitro-verfahren zum screening zugänglicher biologischer marker in krankhaften geweben

Country Status (6)

Country Link
US (1) US20090163414A1 (de)
EP (3) EP1806587A1 (de)
JP (1) JP5089607B2 (de)
AT (1) ATE473447T1 (de)
DE (1) DE602006015358D1 (de)
WO (1) WO2007080039A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130331294A1 (en) * 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009138392A1 (en) * 2008-05-14 2009-11-19 ETH Zürich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
EP2463659A1 (de) * 2010-12-13 2012-06-13 Université de Liège Biomarker für die Krebsdiagnose
EP2463658A1 (de) * 2010-12-13 2012-06-13 Université de Liège Biomarker, Verwendungen von Biomarkern und Verfahren zur Identifizierung von Biomarkern
CN112698025B (zh) * 2020-12-14 2022-10-18 四川沃文特生物技术有限公司 抗原或抗体包被磁微粒的方法、应用及试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336506A (en) * 1986-07-03 1994-08-09 Advanced Magnetics Inc. Targeting of therapeutic agents using polysaccharides
EP1269195A2 (de) 2000-03-20 2003-01-02 Target Protein Technologies, Inc. Verfahren zur identifizierung und isolierung von gewebespezifischen lumenexponierten molekülen
MXPA03006617A (es) * 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
EP1373896A2 (de) * 2001-03-12 2004-01-02 MonoGen, Inc. Auf zellen basierte nachweis und unterscheidung von krankheitszuständen
US20040241160A1 (en) * 2001-07-13 2004-12-02 Yan Wu Vegfr-1 antibodies to treat breast cancer
AU2002323120A1 (en) * 2001-08-13 2003-03-03 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
US7422865B2 (en) * 2003-01-13 2008-09-09 Agilent Technologies, Inc. Method of identifying peptides in a proteomic sample
JP2005073621A (ja) * 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
US20060178833A1 (en) * 2005-02-04 2006-08-10 Bauer Kenneth D System for and method of providing diagnostic information through microscopic imaging

Also Published As

Publication number Publication date
US20090163414A1 (en) 2009-06-25
JP2009522562A (ja) 2009-06-11
EP1969376A1 (de) 2008-09-17
WO2007080039A1 (en) 2007-07-19
EP1969376B1 (de) 2010-07-07
EP1806587A1 (de) 2007-07-11
JP5089607B2 (ja) 2012-12-05
EP2226638A2 (de) 2010-09-08
EP2226638A3 (de) 2010-12-15
DE602006015358D1 (de) 2010-08-19

Similar Documents

Publication Publication Date Title
DE602006020710D1 (de) Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
ATE493511T1 (de) Oligonukleotide zur brustkrebsdiagnose
MY153198A (en) Inhibitors of protein aggregation
PH12013502192A1 (en) Antibodies against human angiopoietin 2
ITPD20050266A1 (it) Apparato per il trattamento di patologie di origine malformativa e traumatica afferenti l'area del ginocchio
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
EP4269563A3 (de) Anti-gd2-antikörper
CL2009000742A1 (es) Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.
CL2008002107A1 (es) Formas polimórficas del ácido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1´h,3h-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-[(metilamino]carbonil]fenoxi}-2-metilpropanoico; proceso de preparacion; composición farmacéutica; dispositivo farmacéutico; y uso en el tratamiento de enfermedades respiratorias.
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
DE602005019762D1 (de) Medizinisches Instrument zum Manipulieren, insbesondere zum Zurückziehen des Gewebes oder des Organes.
DE602005016127D1 (de) Substituierte hydantoine zur krebsbehandlung
FR2916047B1 (fr) Procede et systeme pour caracteriser un tissu biologique.
ATE473447T1 (de) In-vitro-verfahren zum screening zugänglicher biologischer marker in krankhaften geweben
EP1862433A4 (de) Personalisierter synthetischer diamant mit verschiedenen farben, erhalten aus keratin (lebender oder toter) menschen oder tiere und herstellungsverfahren dafür
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
EA201101531A1 (ru) Способ лечения острого миелоидного лейкоза
MX2009008560A (es) Sondas para diagnostico por la imagen.
ECSP066797A (es) Procedimientos para la preparacion de halogenuros de aril- y heteroarilalquilsulfonilo
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
BRPI1014222A2 (pt) composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar
EA201000141A1 (ru) Новые триазены для лечения рака
FR2897940B1 (fr) Procede de coloration d'un tissu par fluorescence.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties